The cancer immunotherapies market is projected to witness rapid growth at a compound annual growth rate (CAGR) of 23.9%, according to a report by GBI Research.
Titled ‘Global Cancer Immunotherapies Market to 2022’, the report forecasts the cancer immunotherapies market to increase from $16.9bn in 2015 to $75.8bn by 2022.
Go deeper with GlobalData
There are currently 2,037 products in development, with the majority being early stage products indicating the hurdles associated with progressing development, from pre-clinical to clinical stage.
The imbalance between early stage and late-stage products reflects the difficulties in developing cancer immunotherapies, notes Yasser Mushtaq, Senior Analyst for GBI Research. Despite the hurdles, there is a strong interest towards investment in the therapy class, which may help in moving products from early stage to late-stage development.
A number of late-stage products and already marketed drugs are expected to achieve blockbuster status during the forecast period. AstraZeneca’s durvalumab and tremelimumab, Novartis’ CTL-019 and Kite Pharma’s KTE-C19 CAR are some of the notable products anticipated to achieve blockbuster status.
See Also:
A number of existing blockbuster therapies such as Revlimid, Opdivo, Keytruda and Gazyva are also expected to achieve strong revenue growth. Revenues of Keytruda and Opdivo are projected to rise by $7bn and $9bn respectively, while Revlimid is also projected to achieve similar levels of growth, adds Mushtaq.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
